Holen Sie sich die Stockscreener-App
810.24
0.53%
4.31
Handel nachbörslich:
810.50
0.26
+0.03%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Promising Biotech Stocks To Watch TodayAugust 18th - MarketBeat
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact The Gross Law Firm - PR Newswire
Regeneron ends eye disease study due to antibody’s safety profile - BioSpace
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - TMX Newsfile
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile - BioSpace
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Resilient Regeneron stock trades close to 52-week high as dividend and earnings support valuation - AD HOC NEWS
UNIVEST FINANCIAL Corp Takes $8.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action LawsuitHagens Berman Sobol Shapiro LLP - PR Newswire
Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Invests $160.53 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron halts early-stage uveitis trial after safety event - The Pharma Letter
4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI - MarketBeat
Deutsche Bank AG Makes New $323.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grandfield & Dodd LLC Purchases Shares of 36,628 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,778 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by B & T Capital Management DBA Alpha Capital Management - MarketBeat
Samsung Biologics? No — Samchundang Pharm Reaches Landmark Settlement in Eylea Biosimilar Patent Dispute, Clearing Path for Global Commercialization - finance.biggo.com
Regeneron Pharmaceuticals, Inc. Notice of September 14, - globenewswire.com
Resilient Regeneron stock hovers near 52-week high after dividend and analyst target hike - AD HOC NEWS
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron - GlobeNewswire
Biotech Stocks To ResearchAugust 17th - MarketBeat
Can Regeneron Pharmaceuticals (NASDAQ:REGN) Extend Its Run? - Kalkine Media
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
REGN Maintained by Leerink Partners -- Price Target Raised to $8 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners - MarketBeat
Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating - marketscreener.com
Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks - TradingView
7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments - MarketBeat
How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story - simplywall.st
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy - MarketBeat
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - fool.com
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - finance.yahoo.com
Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines - finance.biggo.com
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Regeneron Genetics Center's Andy Deubler: The AI-Era Genomics Race Will Be Decided by Curation, Not Volume - finance.biggo.com
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class ... - Caledonian Record
Bernstein raises Regeneron stock price target to $756 on Eylea beat - Investing.com
BMS builds big in Texas; Regeneron backs would-be rival - Pharma Voice
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating - marketscreener.com
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Regeneron Director Kathryn Guarini Executes 400 Stock Options and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Regeneron Director Huda Y. Zoghbi Executes Stock Option and Sells Shares on August 10, 2026 - Kalkine Media
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $320,000.00 in Stock - MarketBeat
REGN Stockholders May Be Entitled to Lead the Class Action - GlobeNewswire
REGN DEADLINE: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
REGN Looks 7.8% Undervalued on GF Value™ Amid Strong Market Position - GuruFocus
Wedge Capital Management L L P NC Purchases 8,063 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Insight Wealth Strategies LLC Has $5.46 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA) - Seeking Alpha
How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock - Trefis
Handelsbanken Fonder AB Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alameda biotech Infinimmune scores $75 million as it plans first clinical trials - The Business Journals
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):